# Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)

> **NCT01705223** · PHASE2 · COMPLETED · sponsor: **National Center for AIDS/STD Control and Prevention, China CDC** · enrollment: 150 (actual)

## Conditions studied

- AIDS

## Interventions

- **BIOLOGICAL:** DNA vaccine
- **BIOLOGICAL:** DNA vaccine prime with the addition of electroporation
- **BIOLOGICAL:** rTV boost
- **BIOLOGICAL:** rTV boost
- **BIOLOGICAL:** rTV boost

## Key facts

- **NCT ID:** NCT01705223
- **Lead sponsor:** National Center for AIDS/STD Control and Prevention, China CDC
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2014-10
- **Final completion:** 2015-01
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2015-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01705223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01705223, "Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01705223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*